Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601255 | 0.97 | L3MBTL1 (0.68) | L3MBTL1TDP1HRH4HRH3SPHK1 | |
| SCHEMBL20534698 | 0.87 | TDP1 (0.75) | L3MBTL1TDP1HRH4HRH3SPHK1 | |
| SCHEMBL3446778 | 0.87 | TDP1 (0.75) | L3MBTL1TDP1HRH4HRH3SPHK1 | |
| SCHEMBL8327886 | 0.85 | TDP1 (0.45) | L3MBTL1TDP1HRH4HRH3SPHK1 | |
| SCHEMBL27492044 | 0.85 | TDP1 (0.45) | L3MBTL1TDP1HRH4HRH3SPHK1 | |
| SCHEMBL2186600 | 0.83 | APP (0.53) | L3MBTL1TDP1HRH4HRH3APP | |
| SCHEMBL3438748 | 0.83 | TDP1 (0.60) | L3MBTL1TDP1HRH4HRH3TSHR | |
| SCHEMBL1835993 | 0.82 | TDP1 (0.69) | L3MBTL1TDP1SPHK1 | |
| SCHEMBL7598315 | 0.81 | L3MBTL1 (0.56) | L3MBTL1TDP1HRH4HRH3SPHK1 | |
| SCHEMBL25195898 | 0.81 | TSHR (0.64) | L3MBTL1TDP1HRH4HRH3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417384-B1 | SUPERIOR IMAGING AND VISUALIZATION OF NEOPLASTIC LESIONS; TUMOR-SPECIFIC CYTOTOXIC CANCER THERAPY, DIAGNOSIS AND TREATMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-07-09 | — | — | US | disclosed |
| US-20020065429-A1 | Radioiodinated phospholipid ether analogs and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-05-30 | — | — | US | disclosed |
| US-6255519-B1 | RADIOLABELLED PHARMACEUTICALS AND BIOLOGICAL PROBES UEFUL IN CANCER DIAGNOSIS AND TREATMENT; IMAGING TECHNOLOGY | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065429-A1 | Radioiodinated phospholipid ether analogs and methods of using the same | PHOSPHO1, CDIPT, LPCAT3 | L3MBTL1 1500/4885TDP1 2906/4885HRH4 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.